GeneDx is trading 5.05% higher at $64.36; no clear company-specific catalyst was confirmed for the October 27 move.

  • An October 27 page on positive Seattle Children’s rapid genome sequencing findings cites an August 24 press release, not a new announcement.
  • The move follows a 9.10% October 26 gain and an October 23 sell-off; recent reporting said the rebound lacked a clear company-specific catalyst.
  • October 27 major-index moves were mixed and modest; evidence does not establish a broader-market cause.